New Jersey is currently home to 1712 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
NCT04593784
Recruiting
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2023
Locations: Frontage Clinical Services, Secaucus, New Jersey
Conditions: Healthy
Register for Updates
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
NCT02848274
Recruiting
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Gender:
All
Ages:
All
Trial Updated:
07/17/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Mycosis Fungoides, Non-Hodgkin's Lymphoma
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
All
Ages:
All
Trial Updated:
07/17/2023
Locations: RANGER: Multi-Disciplinary Specialists, Rutherford, New Jersey
Conditions: Peripheral Nerve Injuries
Register for Updates
A Multilevel Intervention to Improve Adherence to Childhood Cancer Survivorship
NCT05448560
Recruiting
More than 80% of childhood cancer survivors develop serious or life-threatening late effects after cancer therapy, but <20% receive recommended survivorship care offered at cancer center survivorship clinics. In a shared care model, the investigators propose to investigate an innovative multi-level intervention consisting of: 1) patient survivorship education via telehealth with the cancer center, 2) ongoing patient-tailored education program within the electronic health record patient portal, 3... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
07/13/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Childhood Cancer, Survivorship, Health Care Utilization, Health Knowledge, Attitudes, Practice, Adherence, Patient
Register for Updates
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608
Recruiting
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/13/2023
Locations: Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Register for Updates
Meeting an Unmet Need in Multiple Sclerosis
NCT05953519
Recruiting
The primary objectives of this study is to examine the efficacy of the Unified Protocol in decreasing depression and anxiety among individuals with MS and the secondary outcomes (e.g., improved well-being, QOL, coping, etc.) that may occur in tandem.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
Re-Connect Application for Smoking Cessation
NCT05224154
Recruiting
This series of studies will explore the acceptability, feasibility, and preliminary efficacy of making access to smartphone applications contingent on objective evidence of smoking abstinence.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: Rowan University, Glassboro, New Jersey
Conditions: Smoking Cessation, Acceptability of Health Care, Nicotine Dependence, Cigarettes
Register for Updates
Increasing MAT Engagement With Financial Incentives
NCT04585399
Recruiting
The increased prevalence of opioid use disorder (OUD) and associated overdoses and adverse events has led to a substantial increase in the number of patients being seen at emergency departments (ED). Thus, the ED may be an ideal location for identifying patients in need of OUD treatment and can serve as the first touch point in the OUD continuum of care to promote medication assisted treatment initiation. Contingency management (CM) is an effective method for promoting treatment initiation and a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: Cooper University Hospital, Camden, New Jersey
Conditions: Opioid-use Disorder
Register for Updates
Using MASL to Combat Oral Cancer
NCT04188665
Recruiting
This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).
Gender:
All
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: New Jersey Medical School, Newark, New Jersey
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
NCT03257163
Recruiting
This phase II trial studies how well pembrolizumab works with capecitabine and radiation therapy in treating patients with mismatch repair deficient and Epstein-Barr virus positive gastric cancer. Monoclonal antibodies, such as pembrolizumab may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them fro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7, Stage IIIC Gastric Cancer AJCC v7
Register for Updates
Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry
NCT05915078
Recruiting
This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients aged from 6 months to 17 years of age who are undergoing an in-office ear tube placement procedure (tympanostomy) using the Tula® System. The Registry will include up to 20 centers in the US and up to 200 patients for the initial evaluation. The FDA-approved Tula System includes the Tula Iontophoresis System (IPS) with TYMBION™ otic anesthetic for local anesthesia of the ea... Read More
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
07/06/2023
Locations: Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
Conditions: Otitis Media With Effusion, Acute Otitis Media, Otitis Media
Register for Updates
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
NCT05943210
Recruiting
This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
07/03/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Rectal Cancer
Register for Updates